Short answer
AVITA Medical, Inc. (RCEL) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for the quarter ended September 30, 2026.
AVITA Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for the quarter ended September 30, 2026
- Financial details and management commentary contained in Exhibit 99.1 press release
- Results update provides investors the company’s latest operating and financial performance
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $26.1M, up 53% year over year and 20% sequentially, led by RECELL and growing Cohealyx adoption
- Gross margin 84.0%, up from 81.3%, while operating expenses reached $24.6M, limiting operating leverage
- Net loss narrowed to $6.2M, or $0.20 per share, from $13.2M, or $0.46 per share, despite $2.1M warrant revaluation expense
- 2026 revenue guidance raised to $92M-$94M from $86M-$89M, with Q4 cash-flow breakeven reaffirmed
- $10M credit-facility tranche drawn after reaching $85M trailing revenue, raising total borrowings to $60M and improving liquidity as cash ended at $10.5M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVITA Medical, Inc. 8-K filings
Get the next RCEL 8-K as it lands
Follow RCEL for push alerts, or ask the research agent what this filing means.